| Paris | |
| 35 | |
| Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech that specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. | |
| The companys lead drug candidate, SENS-111, is a small molecule which aims to treat acute vertigo. It is the first representative of the histamine type 4 receptor antagonist class tested in inner-ear pathologies. It can be taken orally and has just been successfully assessed in humans in phase 1b clinical trial. | |
| NGUYEN Laurent | |
| www.sensorion-pharma.com | |
| ALSEN:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 6 fois.